arrow
Back
R

Robert J. Jones

beatson oncology centre

67H-index
431Paper Count
2.9WCitation Count
Published Papers 124
Publication Date
UK real-world data of radium-223 dichloride in metastatic prostate cancer
err2025-12-01
err0
PREAI
errRandhawa, Manreet; Buchanan, Gail; Stratton, Irene M.; Race, Gemma; Challapalli, Amar; Bottomley, David; Logue, John; Sundar, Santhanam; Robinson, Angus; Mclaren, Duncan B.; Stevenson, Robert; O'sullivan, Joe M.; Sweeney, Loretta; Mcgrane, John; Jiang, Xue; Mazhar, Danish; Khoo, Vincent; Mcphail, Neil; Jones, Rob J.
errShare
errSave
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]
err2025-11-13
err0
PREAI
errArun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
errShare
errSave
Accuracy of glomerular filtration rate estimates among patients with cancer
err2025-09-19
err0
errOAAI
errJennifer S. Lees; Edouard L. Fu; Anne-Laure Faucon; Benjamin MP Elyan; Lesley A. Inker; Andrew S. Levey; Robert J. Jones; Richard H. Wilson; Patrick B. Mark; Juan-Jesus Carrero
errShare
errSave
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
errCell
IF42.5
err2025-08-26
err0
errOAAI
errEmily Grist; Peter Dutey-Magni; Marina A. Parry; Larissa Mendes; Ashwin Sachdeva; James A. Proudfoot; Anis A. Hamid; Mazlina Ismail; Sarah Howlett; Stefanie Friedrich; Lia DePaula Oliveira; Laura Murphy; Christopher Brawley; Oluwademilade Dairo; Sharanpreet Lall; Yang Liu; Daniel Wetterskog; Anna Wingate; Karolina Nowakowska; Leila Zakka; Claire L. Amos; Nafisah B. Atako; Victoria Wang; Hannah L. Rush; Robert J. Jones; Hing Leung; William R. Cross; Silke Gillessen; Chris C. Parker; Teresa Marafioti; Alfonso Urbanucci; Matthew Fittall; Edward M. Schaeffer; Daniel E. Spratt; David Waugh; Thomas Powles; Matthew R. Sydes; Felix Y. Feng; Daniel M. Berney; Mahesh K.B. Parmar; Noel W. Clarke; Elai Davicioni; Tamara L. Lotan; Christopher J. Sweeney; Louise C. Brown; Nicholas D. James; Gerhardt Attard
errShare
errSave
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
err2025-07-16
err0
errOAAI
errC. Jones; P. Dutey-Magni; L.R. Murphy; M.L. Murray; J.E. Brown; E. McCloskey; M. Brown; C.L. Amos; D.C. Gilbert; R.J. Jones; W. Cross; D. Matheson; R. Millman; M.K.B. Parmar; G. Attard; M.R. Sydes; L.C. Brown; N.D. James; N.W. Clarke; A. Sachdeva
errShare
errSave
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
err2025-07-16
err0
PREAI
errNeeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
errShare
errSave
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
err2025-07-16
err0
PREAI
errKarim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal
errShare
errSave
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
err2025-07-07
err0
errOAAI
errSilke Gillessen; Laura Murphy; Nicholas D James; Ashwin Sachdeva; Omar El-Taji; Hoda Abdel-Aty; Amanda I Adler; Claire Amos; Gerhardt Attard; Mohini Varughese; Joanna Gale; Simon Brown; Narayanan Srihari; Alison J Birtle; Mick Brown; Kitty Chan; Simon Chowdhury; William Cross; David P Dearnaley; Omar Din; Peter Dutey-Magni; Duncan C Gilbert; Clare Gilson; Struan Gray; Emily Grist; Uschi Hofmann; Andrew M Hudson; Yatin Jain; Ganesan Jeyasangar; Robert Jones; Mahaz Kayani; Ruth E Langley; Zafar Malik; Malcolm D Mason; David Matheson; Connor McAlpine; Archie Macnair; Robin Millman; Claire Murphy; Minal Padden-Modi; Omi Parikh; Chris Parker; Hannah Rush; Martin Russell; Rajaguru Srinivasan; Santhanam Sundar; Jacob S Tanguay; Fabio Turco; Patrick Williams; Matthew R Sydes; Mahesh K B Parmar; Louise C Brown; Noel W Clarke
errShare
errSave
Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis
err2025-03-21
err0
errOAAI
errElyan, Benjamin M. P.; Tan, Beatrix; Lambourg, Emilie; Mcallister, David A.; Jones, Rob J.; Lang, Ninian N.; Mark, Patrick B.; Lees, Jennifer S.; Bell, Samira
errShare
errSave
Occupational incidence of bladder cancer amongst veteran ammunition technicians of the British Army
err2025-03-01
err0
errOAAI
errCollett, Gareth; Bashford, Tim; Whitehead, Nik J.; Kazimierska, Ewa; Swamy, Gokul Vignesh Kanda; Jones, Robert J.; Van Hemelrijck, Mieke; Bryan, Richard T.
errShare
errSave
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
err2024-12-01
err0
errOAAI
errAzad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj
errShare
errSave
A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
err2024-09-01
err0
PREAI
errAggarwal, R.; Tagawa, S. T.; Monk, P.; Zhu, X.; Jones, R. J.; Linch, M.; Costin, D.; de Bono, J. S.; Karsh, L. I.; Petrylak, D. P.; Borderies, P.; Deshpande, R.; O'Neill, V.; Zhang, J.
errShare
errSave
Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
err2024-09-01
err1
PREAI
errAgarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.
errShare
errSave
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
err2024-08-12
err1
PREAI
errGraff, Julie N.; Hoimes, Christopher J.; Gerritsen, Winald R.; Vaishampayan, Ulka N.; Elliott, Tony; Hwang, Clara; ten Tije, Albert J.; Omlin, Aurelius; McDermott, Raymond S.; Fradet, Yves; Tagawa, Scott T.; Kilari, Deepak; Ferrario, Cristiano; Uemura, Hiroji; Jones, Robert J.; Fukasawa, Satoshi; Peer, Avivit; Niu, Cuizhen; Poehlein, Christian H.; Qiu, Ping; Suttner, Leah; de Wit, Ronald; Schloss, Charles; de Bono, Johann S.; Antonarakis, Emmanuel S.
errShare
errSave
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
err2024-08-01
err0
errOAAI
errCollinson, Fiona; Royle, Kara-Louise; Swain, Jayne; Ralph, Christy; Maraveyas, Anthony; Eisen, Tim; Nathan, Paul; Jones, Robert; Meads, David; Wah, Tze Min; Martin, Adam; Bestall, Janine; Kelly-Morland, Christian; Linsley, Christopher; Oughton, Jamie; Chan, Kevin; Theodoulou, Elisavet; Arias-Pinilla, Gustavo; Kwan, Amy; Daverede, Luis; Handforth, Catherine; Trainor, Sebastian; Salawu, Abdulazeez; McCabe, Christopher; Goh, Vicky; Buckley, David; Hewison, Jenny; Gregory, Walter; Selby, Peter; Brown, Julia; Brown, Janet
errShare
errSave
Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus
err2024-07-22
err1
errOAAI
errHarding, Thomas A.; Martin, Richard M.; Merriel, Samuel W. D.; Jones, Robert; O'Sullivan, Joe M.; Kirby, Mike; Olajide, Oluwabunmi; Norman, Alexander; Bhatt, Jaimin; Hulson, Oliver; Martins, Tanimola; Gnanapragasam, Vincent J.; Aning, Jonathan; Burgess, Meg; Rosario, Derek J.; Pashayan, Nora; Tesfai, Abel; Norori, Natalia; Rylance, Amy; Seggie, Andrew
errShare
errSave
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer
err2024-07-12
err1
errOAAI
errAgarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim
errShare
errSave
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
err2024-07-01
err1
errOAAI
errRescigno, Pasquale; Porta, Nuria; Finneran, Laura; Riisnaes, Ruth; Figueiredo, Ines; Carreira, Suzanne; Flohr, Penny; Miranda, Susana; Bertan, Claudia; Ferreira, Ana; Crespo, Mateus; Rodrigues, Daniel Nava; Gurel, Bora; Nobes, Jenny; Crabb, Simon; Malik, Zafar; Ralph, Christy; McGovern, Ursula; Hoskin, Peter; Jones, Robert J.; Birtle, Alison; Gale, Joanna; Sankey, Peter; Jain, Suneil; McLaren, Duncan; Chadwick, Eliot; Espinasse, Aude; Hall, Emma; de Bono, Johann
errShare
errSave
TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
err2024-04-05
err3
PREAI
errPiulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj
errShare
errSave
Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
err2024-04-05
err0
PREAI
errLiu, Glenn; Mu, Xinmeng Jasmine; Fizazi, Karim; Laird, A. Douglas; Matsubara, Nobuaki; Yip, Steven M.; Pu, Jie; Carles, Joan; Fay, Andre P.; Jones, Robert J.; Zschaebitz, Stefanie; Piulats, Josep M.; Joung, Jae Young; Roh, Whijae; Chelliserry, Jijumon; Di Santo, Nicola; Saul, Michelle; Azad, Arun A.; Agarwal, Neeraj
errShare
errSave